Medical Disposables & Consumables Players Face Challenge of Government-Initiated Price Cuts in China
5一20扫雷群when the chinese government started to slash the drug prices in 2018, we knew that it was only a matter of time before medical consumables would be affected.
Possibility for Examination to be Included in the SHI Fee Scale Brings More Certainty for Reimbursement for New Diagnostics in Germany
in the past, the inclusion of new diagnostic tests in the ebm was not transparent, with unclear timelines and requirements and manufacturers were unable to...
as a critical element of accelerating the healthcare payment reform, the pilot of diagnosis related groups in 30 major cities across china was officially announced in june by state administrations including...
5一20扫雷群quality is not anymore limited to the functional and esthetic products features and its handling use. the attention is now focused on the commercialization phase, innovative and efficacy features, profitability and usability of instruction for final users, as well as eco-friendly features...
china: 2018 was another eventful year for the pharmaceutical industry, highlighted by the chinese government’s radical attempts to slash drug prices by the annual national drug price negotiation and along with the introduction of a national procurement program.
Press Releases and Publications
Diagnostics Developers Rapidly Utilizing New Payment Codes Established by PAMA
7 november 2018
access the article from 360dx .
Compliance Conundrum: Genomic Health Faces DoJ Investigation after CMS Changes Date of Service Regs
5一20扫雷群genomic health has disclosed that it is the subject of a u.s. department of justice investigation into its compliance with changes that took effect in january to medicare’s date of service billing regulation. adam crowther, manager, spoke with clinical omics about the impact on diagnostics companies.
Medical Device & Diagnostics Industry
Considering Market Access Risk as Part of Today’s M&A Process
5一20扫雷群in an exclusive published today in medical device and diagnostics industry, vice president, rob wenthold discusses the key market access issues examined during the m&a process and demonstrates the importance of market access to inform m&a through case studies and business decision-making in general.
Boston Healthcare Adds Seasoned Market Access Leader to Global Life Science Consulting Team.
Cost-Conscious MedSeq Project Provides Snapshot to Suggest Genomic Sequencing does not Increase Downstream Healthcare Costs
5一20扫雷群ceo, joseph v. ferrara commented on the value sequencing might bring to the clinical setting in the may-june 2018 issue of clinical omics.
Global Business Reports
United States Biopharmaceuticals 2018
thomas f. goss spoke to global business reports on the us biopharmaceutical industry.
Real-World Evidence in the Era of Advanced Diagnostics
5一20扫雷群shivang doshi, director at boston healthcare wrote an op-ed for the march-april edition of clinical omics on real-world evidence for advanced diagnostics.
International Regulatory Group Proposes Principles for Evaluating Safety, Performance of Diagnostics
joseph v. ferrara, ceo of boston healthcare spoke with 360dx news about the proposed principles for safety and performance of medical devices, including ivd medical devices, put forward by the international medical device regulators forum (imdrf).
Year in Pharma
senior vice president, thomas f. goss speaks with lisa jarvis from c&en